Goldman Sachs Group Inc Veracyte, Inc. Transaction History

Goldman Sachs Group Inc

$613 Billion
Q4 2024

A detailed history of Goldman Sachs Group Inc transactions in Veracyte, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,216,472 shares of VCYT stock, worth $40.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,216,472

Previous 1,313,494 7.39%

Holding current value

$40.3 Million

Previous $44.7 Million 7.77%

% of portfolio

0.01%

Previous 0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	SELL	$31.92 - $44.4 $3.1 Million - $4.31 Million	-97,022 Reduced 7.39%	1,216,472 $48.2 Million
Q3 2024 Nov 14, 2024	BUY	$21.0 - $35.25 $4.67 Million - $7.84 Million	222,294 Added 20.37%	1,313,494 $44.7 Million
Q2 2024 Aug 13, 2024	BUY	$18.86 - $23.55 $2.15 Million - $2.69 Million	114,111 Added 11.68%	1,091,200 $23.6 Million
Q1 2024 May 15, 2024	SELL	$21.0 - $29.1 $5.02 Million - $6.95 Million	-238,857 Reduced 19.64%	977,089 $21.7 Million
Q4 2023 Feb 13, 2024	SELL	$19.72 - $28.68 $1.78 Million - $2.59 Million	-90,216 Reduced 6.91%	1,215,946 $33.5 Million
Q3 2023 May 14, 2024	BUY	$22.33 - $29.92 $2.01 Million - $2.7 Million	90,216 Added 7.42%	1,306,162 $29.2 Million
Q3 2023 Nov 14, 2023	BUY	$22.33 - $29.92 $838,513 - $1.12 Million	37,551 Added 2.96%	1,306,162 $29.2 Million
Q2 2023 May 14, 2024	SELL	$20.96 - $26.99 $3.06 Million - $3.94 Million	-146,152 Reduced 10.33%	1,268,611 $32.3 Million
Q2 2023 Aug 14, 2023	SELL	$20.96 - $26.99 $3.06 Million - $3.94 Million	-146,152 Reduced 10.33%	1,268,611 $32.3 Million
Q1 2023 May 14, 2024	BUY	$20.58 - $27.89 $4.05 Million - $5.49 Million	196,974 Added 16.17%	1,414,763 $31.5 Million
Q1 2023 May 11, 2023	BUY	$20.58 - $27.89 $4.05 Million - $5.49 Million	196,974 Added 16.17%	1,414,763 $31.5 Million
Q4 2022 May 14, 2024	SELL	$15.31 - $29.94 $1.7 Million - $3.32 Million	-110,740 Reduced 8.34%	1,217,789 $28.9 Million
Q4 2022 Feb 13, 2023	SELL	$15.31 - $29.94 $1.7 Million - $3.32 Million	-110,740 Reduced 8.34%	1,217,789 $28.9 Million
Q3 2022 May 14, 2024	BUY	$16.58 - $27.9 $4.62 Million - $7.78 Million	278,684 Added 26.55%	1,328,529 $22.1 Million
Q3 2022 Nov 10, 2022	BUY	$16.58 - $27.9 $4.62 Million - $7.78 Million	278,684 Added 26.55%	1,328,529 $22.1 Million
Q2 2022 May 14, 2024	SELL	$15.45 - $29.52 $2.57 Million - $4.9 Million	-166,101 Reduced 13.66%	1,049,845 $20.9 Million
Q2 2022 Aug 15, 2022	BUY	$15.45 - $29.52 $8.9 Million - $17 Million	575,949 Added 121.53%	1,049,845 $20.9 Million
Q1 2022 May 16, 2022	BUY	$21.94 - $42.51 $1.28 Million - $2.47 Million	58,195 Added 14.0%	473,896 $13.1 Million
Q4 2021 Feb 14, 2022	BUY	$36.09 - $53.79 $623,851 - $929,813	17,286 Added 4.34%	415,701 $17.1 Million
Q3 2021 Nov 10, 2021	BUY	$35.62 - $52.97 $14.2 Million - $21.1 Million	398,415 New	398,415 $18.5 Million

Others Institutions Holding VCYT

# of Institutions

338

Shares Held

76.3M

Call Options Held

212K

Put Options Held

18.5K

View Full List

About VERACYTE, INC.

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.37B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

More about VCYT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Veracyte, Inc. Transaction History